Incretin Analogs for Weight Management in Adults Without Diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37522468/
All incretin analogs in this review are superior to placebo when used for weight management in adults without diabetes.
Conclusions: All incretin analogs in this review are superior to placebo when used for weight management in adults without diabetes.
Share
Conclusions/Relevance: Discontinuation of Ozempic should be considered prior to general anesthesia due to gastrointestinal side effects including delayed gastric emptying. As the popularity of Ozempic grows, facial plastic surgeons must be aware of both the impact on facial appearance and perioperative consideration.
Share
Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity
Source : https://www.sciencedirect.com/science/article/abs/pii/S0196978123001365?via=ihub
Novel dual agonists for the glucagon-like peptide-1 (GLP-1) and Y2 receptor hold the potential for enhanced efficacy over GLP-1 receptor (GLP-1R) agon...
Conclusions/Relevance: These results indicate the potential of developing xGLP/PYY-6 as an antiobesity, lipid regulation, antisteatotic, and antidiabetic agent.
Share
Pediatric Obesity: Complications and Current Day Management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37511966/
Obesity affects approximately 1 in 5 youth globally and increases the risk of complications during adolescence and young adulthood, including type 2 diabetes, dyslipidemia, hypertension, non-alcoholic fatty liver disease, obstructive...
Conclusions/Relevance: Once identified, pediatric obesity should always be managed with lifestyle modification. However, adolescents with obesity may also benefit from anti-obesity medications (AOM), several of which have been approved for use in adolescents by the US Food and Drug Administration, including liraglutide,...
Share
The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials - Diabetology & Metabolic Syndrome
Source : https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-023-01118-6
Aim We aimed to assess the association between the use of Glucagon-like peptide-1 receptor agonists and the risk of 12 respiratory diseases in patients with type 2 diabetes, obesity, or...
Conclusion: In conclusion, GLP-1RAs were linked to a lower risk of overall respiratory diseases, especially Pulmonary edema and Bronchitis. In the future, physicians should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases and evaluate the efficacy of GLP-1RAs in the primary and secondary prevention of...
Share